Pacific Biosciences Of California (PACB) Invested Capital (2010 - 2026)

Pacific Biosciences Of California has reported Invested Capital for 17 years, with the latest figure at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 97.42% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (down 97.42% YoY), and the FY2025 full-year result was $5.3 million, down 98.94% from the prior year.
• Invested Capital for Q1 2026 stood at $2.4 million, down from $5.3 million in the prior quarter.
• The five-year high for Invested Capital was $1.1 billion in Q2 2023, with the low at $2.4 million in Q1 2026.
• Average Invested Capital over 5 years is $506.8 million, with a median of $626.6 million recorded in 2022.
• Year-over-year, Invested Capital soared 164.05% in 2022 and slumped 98.94% in 2025.
• Tracing PACB's Invested Capital over 5 years: stood at $735.0 million in 2022, then slipped by 4.58% to $701.3 million in 2023, then dropped by 27.76% to $506.6 million in 2024, then tumbled by 98.94% to $5.3 million in 2025, then sank by 55.77% to $2.4 million in 2026.
• The last three Invested Capital figures came in at $2.4 million (Q1 2026), $5.3 million (Q4 2025), and $36.1 million (Q3 2025), per Business Quant data.

Peer Comparison